カテゴリー： GlobalInfoResearch, 世界, 医療/バイオ

世界の低血糖薬市場2022年：インスリン、DPP-4、GLP-1、SGLT-2、その他

◆英語タイトル：Global Hypoglycemic Drugs Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028
	◆商品コード：GIR22MY8849 ◆発行会社（リサーチ会社）：GlobalInfoResearch ◆発行日：2022年5月（※2025年版があります。お問い合わせください。） ◆ページ数：101 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（注文後2-3日） ◆調査対象地域：グローバル ◆産業分野：医薬品

◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,480 ⇒換算￥501,120	見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）	USD5,220 ⇒換算￥751,680	見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）	USD6,960 ⇒換算￥1,002,240	見積依頼/購入/質問フォーム

★GlobalInfoResearchに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

低血糖薬とは、血糖値を下げることを目的とした医薬品の総称です。主に糖尿病の治療に用いられるこれらの薬剤は、血糖値を正常範囲に保つことで合併症のリスクを軽減し、患者の日常生活の質を向上させるために重要な役割を果たしています。

低血糖薬の特徴として、まずその作用機序が挙げられます。これらの薬剤は主に以下のようなメカニズムを通じて血糖値を調整します。第一に、膵臓からのインスリン分泌を促進することにより、血中のグルコースを細胞に取り込ませ、結果的に血糖値を下げる作用を持つ薬剤があります。第二に、肝臓のグルコース産生を抑制することにより、血糖値の上昇を防ぐ成分も存在します。さらに、腸内での糖の吸収を抑制することによって、食後の血糖値の急激な上昇を防ぐ薬剤も取り上げられます。こうした多様な作用機序により、患者の状態に応じて最適な治療が可能となります。

低血糖薬は大きく分けて、いくつかの主要なクラスに分類されます。第一に、スルホニル尿素薬（SU薬）があります。これは膵臓からのインスリン分泌を促進し、血糖値を下げる作用を持つ薬剤です。次に、メトホルミンなどのビグアナイド薬があります。ビグアナイド薬は肝臓のグルコース産生を抑制し、インスリン抵抗性の改善にも寄与します。また、DPP-4阻害薬やGLP-1受容体作動薬など、最近の治療選択肢として注目されているクラスもあります。DPP-4阻害薬は、インクレチンホルモンを分解する酵素を阻害し、インスリン分泌を促進することで血糖を下げます。一方、GLP-1受容体作動薬は、インクレチンホルモンの作用を模倣することで、食欲抑制や胃排出遅延をもたらし、血糖管理に役立っています。

これらの薬剤の用途としては、主に2型糖尿病の治療に使用されますが、最近では1型糖尿病患者にも使用が検討されることが増えています。また、低血糖薬は単独で使用されることもあれば、他の薬剤と併用することによって、治療効果を向上させる場合もあります。たとえば、メトホルミンとスルホニル尿素薬を併用することで、相乗効果を発揮し、より良い血糖コントロールにつながることがあります。

低血糖薬の選択は、患者の年齢、合併症の有無、生活習慣、治療に対する反応など、多くの要因によって左右されます。特に、高齢者や腎機能障害のある患者には、低血糖のリスクや副作用を考慮して慎重な選択が求められます。また、治療においては、血糖値だけでなく、患者の全体的な健康状態や生活の質も重視されるべきです。

関連技術としては、血糖モニタリング技術が挙げられます。最新の血糖測定器具や連続血糖測定器（CGM）を使用することで、患者はリアルタイムで血糖値を把握し、適切な薬剤の使用や食事管理が可能となります。こうした技術は、低血糖のリスクを抑えるだけでなく、患者自身の自己管理能力を高める上でも重要です。

さらに、最近の研究では、低血糖薬が糖尿病患者の心血管疾患リスクに与える影響についても注目が集まっています。一部の薬剤は心血管保護作用を持つことが示されており、治療の選択肢に新たな視点をもたらしています。このような新しい知見は、今後の糖尿病治療の方針にも影響を及ぼすことでしょう。

加えて、生活習慣の改善や栄養管理も低血糖薬と併用する治療法の重要な要素です。患者の日常生活において、適切な食事や運動を取り入れることで、更に効果的な血糖コントロールが期待できます。医療従事者は、患者に対してライフスタイルの変更を促すことも重要な役割となります。

最後に、低血糖薬は、その適正使用において患者教育が不可欠です。患者が自分の病状や治療薬に対する理解を深めることで、治療の遵守が向上し、合併症の予防にもつながります。医療従事者は、患者とコミュニケーションを取りながら、理解を深めてもらう努力を続ける必要があります。

このように、低血糖薬は糖尿病管理において非常に重要な役割を果たしており、その使用は適切な知識と技術に基づいて行われるべきです。近年の技術革新や研究結果を踏まえ、患者一人ひとりに合った最適な治療法の選択が、今後さらに進展することが期待されます。糖尿病患者が豊かで健康な生活を送るためには、低血糖薬だけでなく、総合的なアプローチが求められることを忘れてはなりません。

低血糖薬市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界の低血糖薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

低血糖薬市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・インスリン、DPP-4、GLP-1、SGLT-2、その他

用途別セグメントは次のように区分されます。
・1型糖尿病、2型糖尿病

世界の低血糖薬市場の主要な市場プレーヤーは以下のとおりです。
・Sanofi、Merck & Co.、Novo Nordisk、Eli Lilly、Boehringer Ingelheim、Novartis、Johnson & Johnson、AstraZeneca、Takeda、Bayer、Tonghua DongBao、Hua Dong

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、低血糖薬製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な低血糖薬メーカーの企業概要、2019年～2022年までの低血糖薬の価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な低血糖薬メーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別低血糖薬の販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までの低血糖薬の種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での低血糖薬市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および低血糖薬の産業チェーンを掲載しています。
・第13、14、15章では、低血糖薬の販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
・メーカー情報（企業概要、製品概要、販売量、価格、売上）：Sanofi、Merck & Co.、Novo Nordisk、Eli Lilly、Boehringer Ingelheim、Novartis、Johnson & Johnson、AstraZeneca、Takeda、Bayer、Tonghua DongBao、Hua Dong
・メーカー別市場シェア
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：インスリン、DPP-4、GLP-1、SGLT-2、その他
・用途別分析2017年-2028年：1型糖尿病、2型糖尿病
・低血糖薬の北米市場規模2017年-2028年：アメリカ、カナダ、メキシコ
・低血糖薬のヨーロッパ市場規模2017年-2028年：ドイツ、イギリス、フランス、ロシア、イタリア
・低血糖薬のアジア市場規模2017年-2028年：中国、日本、韓国、インド、東南アジア、オーストラリア
・低血糖薬の南米市場規模2017年-2028年：ブラジル、アルゼンチン
・低血糖薬の中東・アフリカ市場規模2017年-2028年：サウジアラビア、トルコ、エジプト、南アフリカ
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Hypoglycemic Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Hypoglycemic Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Type 1 Diabetes accounting for % of the Hypoglycemic Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Insulin segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Hypoglycemic Drugs include Sanofi, Merck & Co., Novo Nordisk, Eli Lilly, and Boehringer Ingelheim, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Hypoglycemic Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Insulin
DPP-4
GLP-1
SGLT-2
Other
Market segment by Application can be divided into
Type 1 Diabetes
Type 2 Diabetes
The key market players for global Hypoglycemic Drugs market are listed below:
Sanofi
Merck & Co.
Novo Nordisk
Eli Lilly
Boehringer Ingelheim
Novartis
Johnson & Johnson
AstraZeneca
Takeda
Bayer
Tonghua DongBao
Hua Dong
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Hypoglycemic Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Hypoglycemic Drugs, with price, sales, revenue and global market share of Hypoglycemic Drugs from 2019 to 2022.
Chapter 3, the Hypoglycemic Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Hypoglycemic Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Hypoglycemic Drugs market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Hypoglycemic Drugs.
Chapter 13, 14, and 15, to describe Hypoglycemic Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.

❖ レポートの目次 ❖

1 Market Overview
1.1 Hypoglycemic Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Hypoglycemic Drugs Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 Insulin
1.2.3 DPP-4
1.2.4 GLP-1
1.2.5 SGLT-2
1.2.6 Other
1.3 Market Analysis by Application
1.3.1 Overview: Global Hypoglycemic Drugs Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Type 1 Diabetes
1.3.3 Type 2 Diabetes
1.4 Global Hypoglycemic Drugs Market Size & Forecast
1.4.1 Global Hypoglycemic Drugs Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Hypoglycemic Drugs Sales in Volume (2017-2028)
1.4.3 Global Hypoglycemic Drugs Price (2017-2028)
1.5 Global Hypoglycemic Drugs Production Capacity Analysis
1.5.1 Global Hypoglycemic Drugs Total Production Capacity (2017-2028)
1.5.2 Global Hypoglycemic Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Hypoglycemic Drugs Market Drivers
1.6.2 Hypoglycemic Drugs Market Restraints
1.6.3 Hypoglycemic Drugs Trends Analysis
2 Manufacturers Profiles
2.1 Sanofi
2.1.1 Sanofi Details
2.1.2 Sanofi Major Business
2.1.3 Sanofi Hypoglycemic Drugs Product and Services
2.1.4 Sanofi Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Merck & Co.
2.2.1 Merck & Co. Details
2.2.2 Merck & Co. Major Business
2.2.3 Merck & Co. Hypoglycemic Drugs Product and Services
2.2.4 Merck & Co. Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Novo Nordisk
2.3.1 Novo Nordisk Details
2.3.2 Novo Nordisk Major Business
2.3.3 Novo Nordisk Hypoglycemic Drugs Product and Services
2.3.4 Novo Nordisk Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Eli Lilly
2.4.1 Eli Lilly Details
2.4.2 Eli Lilly Major Business
2.4.3 Eli Lilly Hypoglycemic Drugs Product and Services
2.4.4 Eli Lilly Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Boehringer Ingelheim
2.5.1 Boehringer Ingelheim Details
2.5.2 Boehringer Ingelheim Major Business
2.5.3 Boehringer Ingelheim Hypoglycemic Drugs Product and Services
2.5.4 Boehringer Ingelheim Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Novartis
2.6.1 Novartis Details
2.6.2 Novartis Major Business
2.6.3 Novartis Hypoglycemic Drugs Product and Services
2.6.4 Novartis Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Johnson & Johnson
2.7.1 Johnson & Johnson Details
2.7.2 Johnson & Johnson Major Business
2.7.3 Johnson & Johnson Hypoglycemic Drugs Product and Services
2.7.4 Johnson & Johnson Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8 AstraZeneca
2.8.1 AstraZeneca Details
2.8.2 AstraZeneca Major Business
2.8.3 AstraZeneca Hypoglycemic Drugs Product and Services
2.8.4 AstraZeneca Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9 Takeda
2.9.1 Takeda Details
2.9.2 Takeda Major Business
2.9.3 Takeda Hypoglycemic Drugs Product and Services
2.9.4 Takeda Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10 Bayer
2.10.1 Bayer Details
2.10.2 Bayer Major Business
2.10.3 Bayer Hypoglycemic Drugs Product and Services
2.10.4 Bayer Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11 Tonghua DongBao
2.11.1 Tonghua DongBao Details
2.11.2 Tonghua DongBao Major Business
2.11.3 Tonghua DongBao Hypoglycemic Drugs Product and Services
2.11.4 Tonghua DongBao Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12 Hua Dong
2.12.1 Hua Dong Details
2.12.2 Hua Dong Major Business
2.12.3 Hua Dong Hypoglycemic Drugs Product and Services
2.12.4 Hua Dong Hypoglycemic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Hypoglycemic Drugs Breakdown Data by Manufacturer
3.1 Global Hypoglycemic Drugs Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Hypoglycemic Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Hypoglycemic Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Hypoglycemic Drugs Manufacturer Market Share in 2021
3.4.2 Top 6 Hypoglycemic Drugs Manufacturer Market Share in 2021
3.5 Global Hypoglycemic Drugs Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Hypoglycemic Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Hypoglycemic Drugs Market Size by Region
4.1.1 Global Hypoglycemic Drugs Sales in Volume by Region (2017-2028)
4.1.2 Global Hypoglycemic Drugs Revenue by Region (2017-2028)
4.2 North America Hypoglycemic Drugs Revenue (2017-2028)
4.3 Europe Hypoglycemic Drugs Revenue (2017-2028)
4.4 Asia-Pacific Hypoglycemic Drugs Revenue (2017-2028)
4.5 South America Hypoglycemic Drugs Revenue (2017-2028)
4.6 Middle East and Africa Hypoglycemic Drugs Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Hypoglycemic Drugs Sales in Volume by Type (2017-2028)
5.2 Global Hypoglycemic Drugs Revenue by Type (2017-2028)
5.3 Global Hypoglycemic Drugs Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Hypoglycemic Drugs Sales in Volume by Application (2017-2028)
6.2 Global Hypoglycemic Drugs Revenue by Application (2017-2028)
6.3 Global Hypoglycemic Drugs Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Hypoglycemic Drugs Sales by Type (2017-2028)
7.2 North America Hypoglycemic Drugs Sales by Application (2017-2028)
7.3 North America Hypoglycemic Drugs Market Size by Country
7.3.1 North America Hypoglycemic Drugs Sales in Volume by Country (2017-2028)
7.3.2 North America Hypoglycemic Drugs Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Hypoglycemic Drugs Sales by Type (2017-2028)
8.2 Europe Hypoglycemic Drugs Sales by Application (2017-2028)
8.3 Europe Hypoglycemic Drugs Market Size by Country
8.3.1 Europe Hypoglycemic Drugs Sales in Volume by Country (2017-2028)
8.3.2 Europe Hypoglycemic Drugs Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Hypoglycemic Drugs Sales by Type (2017-2028)
9.2 Asia-Pacific Hypoglycemic Drugs Sales by Application (2017-2028)
9.3 Asia-Pacific Hypoglycemic Drugs Market Size by Region
9.3.1 Asia-Pacific Hypoglycemic Drugs Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Hypoglycemic Drugs Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Hypoglycemic Drugs Sales by Type (2017-2028)
10.2 South America Hypoglycemic Drugs Sales by Application (2017-2028)
10.3 South America Hypoglycemic Drugs Market Size by Country
10.3.1 South America Hypoglycemic Drugs Sales in Volume by Country (2017-2028)
10.3.2 South America Hypoglycemic Drugs Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Hypoglycemic Drugs Sales by Type (2017-2028)
11.2 Middle East & Africa Hypoglycemic Drugs Sales by Application (2017-2028)
11.3 Middle East & Africa Hypoglycemic Drugs Market Size by Country
11.3.1 Middle East & Africa Hypoglycemic Drugs Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Hypoglycemic Drugs Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Hypoglycemic Drugs and Key Manufacturers
12.2 Manufacturing Costs Percentage of Hypoglycemic Drugs
12.3 Hypoglycemic Drugs Production Process
12.4 Hypoglycemic Drugs Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Hypoglycemic Drugs Typical Distributors
13.3 Hypoglycemic Drugs Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Hypoglycemic Drugs Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Hypoglycemic Drugs Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Sanofi Basic Information, Manufacturing Base and Competitors
Table 4. Sanofi Major Business
Table 5. Sanofi Hypoglycemic Drugs Product and Services
Table 6. Sanofi Hypoglycemic Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Merck & Co. Basic Information, Manufacturing Base and Competitors
Table 8. Merck & Co. Major Business
Table 9. Merck & Co. Hypoglycemic Drugs Product and Services
Table 10. Merck & Co. Hypoglycemic Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Novo Nordisk Basic Information, Manufacturing Base and Competitors
Table 12. Novo Nordisk Major Business
Table 13. Novo Nordisk Hypoglycemic Drugs Product and Services
Table 14. Novo Nordisk Hypoglycemic Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Eli Lilly Basic Information, Manufacturing Base and Competitors
Table 16. Eli Lilly Major Business
Table 17. Eli Lilly Hypoglycemic Drugs Product and Services
Table 18. Eli Lilly Hypoglycemic Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 20. Boehringer Ingelheim Major Business
Table 21. Boehringer Ingelheim Hypoglycemic Drugs Product and Services
Table 22. Boehringer Ingelheim Hypoglycemic Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Novartis Basic Information, Manufacturing Base and Competitors
Table 24. Novartis Major Business
Table 25. Novartis Hypoglycemic Drugs Product and Services
Table 26. Novartis Hypoglycemic Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 28. Johnson & Johnson Major Business
Table 29. Johnson & Johnson Hypoglycemic Drugs Product and Services
Table 30. Johnson & Johnson Hypoglycemic Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 32. AstraZeneca Major Business
Table 33. AstraZeneca Hypoglycemic Drugs Product and Services
Table 34. AstraZeneca Hypoglycemic Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 35. Takeda Basic Information, Manufacturing Base and Competitors
Table 36. Takeda Major Business
Table 37. Takeda Hypoglycemic Drugs Product and Services
Table 38. Takeda Hypoglycemic Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 39. Bayer Basic Information, Manufacturing Base and Competitors
Table 40. Bayer Major Business
Table 41. Bayer Hypoglycemic Drugs Product and Services
Table 42. Bayer Hypoglycemic Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 43. Tonghua DongBao Basic Information, Manufacturing Base and Competitors
Table 44. Tonghua DongBao Major Business
Table 45. Tonghua DongBao Hypoglycemic Drugs Product and Services
Table 46. Tonghua DongBao Hypoglycemic Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 47. Hua Dong Basic Information, Manufacturing Base and Competitors
Table 48. Hua Dong Major Business
Table 49. Hua Dong Hypoglycemic Drugs Product and Services
Table 50. Hua Dong Hypoglycemic Drugs Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 51. Global Hypoglycemic Drugs Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 52. Global Hypoglycemic Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 53. Market Position of Manufacturers in Hypoglycemic Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 54. Global Hypoglycemic Drugs Production Capacity by Company, (K Units): 2020 VS 2021
Table 55. Head Office and Hypoglycemic Drugs Production Site of Key Manufacturer
Table 56. Hypoglycemic Drugs New Entrant and Capacity Expansion Plans
Table 57. Hypoglycemic Drugs Mergers & Acquisitions in the Past Five Years
Table 58. Global Hypoglycemic Drugs Sales by Region (2017-2022) & (K Units)
Table 59. Global Hypoglycemic Drugs Sales by Region (2023-2028) & (K Units)
Table 60. Global Hypoglycemic Drugs Revenue by Region (2017-2022) & (USD Million)
Table 61. Global Hypoglycemic Drugs Revenue by Region (2023-2028) & (USD Million)
Table 62. Global Hypoglycemic Drugs Sales by Type (2017-2022) & (K Units)
Table 63. Global Hypoglycemic Drugs Sales by Type (2023-2028) & (K Units)
Table 64. Global Hypoglycemic Drugs Revenue by Type (2017-2022) & (USD Million)
Table 65. Global Hypoglycemic Drugs Revenue by Type (2023-2028) & (USD Million)
Table 66. Global Hypoglycemic Drugs Price by Type (2017-2022) & (US$/Unit)
Table 67. Global Hypoglycemic Drugs Price by Type (2023-2028) & (US$/Unit)
Table 68. Global Hypoglycemic Drugs Sales by Application (2017-2022) & (K Units)
Table 69. Global Hypoglycemic Drugs Sales by Application (2023-2028) & (K Units)
Table 70. Global Hypoglycemic Drugs Revenue by Application (2017-2022) & (USD Million)
Table 71. Global Hypoglycemic Drugs Revenue by Application (2023-2028) & (USD Million)
Table 72. Global Hypoglycemic Drugs Price by Application (2017-2022) & (US$/Unit)
Table 73. Global Hypoglycemic Drugs Price by Application (2023-2028) & (US$/Unit)
Table 74. North America Hypoglycemic Drugs Sales by Country (2017-2022) & (K Units)
Table 75. North America Hypoglycemic Drugs Sales by Country (2023-2028) & (K Units)
Table 76. North America Hypoglycemic Drugs Revenue by Country (2017-2022) & (USD Million)
Table 77. North America Hypoglycemic Drugs Revenue by Country (2023-2028) & (USD Million)
Table 78. North America Hypoglycemic Drugs Sales by Type (2017-2022) & (K Units)
Table 79. North America Hypoglycemic Drugs Sales by Type (2023-2028) & (K Units)
Table 80. North America Hypoglycemic Drugs Sales by Application (2017-2022) & (K Units)
Table 81. North America Hypoglycemic Drugs Sales by Application (2023-2028) & (K Units)
Table 82. Europe Hypoglycemic Drugs Sales by Country (2017-2022) & (K Units)
Table 83. Europe Hypoglycemic Drugs Sales by Country (2023-2028) & (K Units)
Table 84. Europe Hypoglycemic Drugs Revenue by Country (2017-2022) & (USD Million)
Table 85. Europe Hypoglycemic Drugs Revenue by Country (2023-2028) & (USD Million)
Table 86. Europe Hypoglycemic Drugs Sales by Type (2017-2022) & (K Units)
Table 87. Europe Hypoglycemic Drugs Sales by Type (2023-2028) & (K Units)
Table 88. Europe Hypoglycemic Drugs Sales by Application (2017-2022) & (K Units)
Table 89. Europe Hypoglycemic Drugs Sales by Application (2023-2028) & (K Units)
Table 90. Asia-Pacific Hypoglycemic Drugs Sales by Region (2017-2022) & (K Units)
Table 91. Asia-Pacific Hypoglycemic Drugs Sales by Region (2023-2028) & (K Units)
Table 92. Asia-Pacific Hypoglycemic Drugs Revenue by Region (2017-2022) & (USD Million)
Table 93. Asia-Pacific Hypoglycemic Drugs Revenue by Region (2023-2028) & (USD Million)
Table 94. Asia-Pacific Hypoglycemic Drugs Sales by Type (2017-2022) & (K Units)
Table 95. Asia-Pacific Hypoglycemic Drugs Sales by Type (2023-2028) & (K Units)
Table 96. Asia-Pacific Hypoglycemic Drugs Sales by Application (2017-2022) & (K Units)
Table 97. Asia-Pacific Hypoglycemic Drugs Sales by Application (2023-2028) & (K Units)
Table 98. South America Hypoglycemic Drugs Sales by Country (2017-2022) & (K Units)
Table 99. South America Hypoglycemic Drugs Sales by Country (2023-2028) & (K Units)
Table 100. South America Hypoglycemic Drugs Revenue by Country (2017-2022) & (USD Million)
Table 101. South America Hypoglycemic Drugs Revenue by Country (2023-2028) & (USD Million)
Table 102. South America Hypoglycemic Drugs Sales by Type (2017-2022) & (K Units)
Table 103. South America Hypoglycemic Drugs Sales by Type (2023-2028) & (K Units)
Table 104. South America Hypoglycemic Drugs Sales by Application (2017-2022) & (K Units)
Table 105. South America Hypoglycemic Drugs Sales by Application (2023-2028) & (K Units)
Table 106. Middle East & Africa Hypoglycemic Drugs Sales by Region (2017-2022) & (K Units)
Table 107. Middle East & Africa Hypoglycemic Drugs Sales by Region (2023-2028) & (K Units)
Table 108. Middle East & Africa Hypoglycemic Drugs Revenue by Region (2017-2022) & (USD Million)
Table 109. Middle East & Africa Hypoglycemic Drugs Revenue by Region (2023-2028) & (USD Million)
Table 110. Middle East & Africa Hypoglycemic Drugs Sales by Type (2017-2022) & (K Units)
Table 111. Middle East & Africa Hypoglycemic Drugs Sales by Type (2023-2028) & (K Units)
Table 112. Middle East & Africa Hypoglycemic Drugs Sales by Application (2017-2022) & (K Units)
Table 113. Middle East & Africa Hypoglycemic Drugs Sales by Application (2023-2028) & (K Units)
Table 114. Hypoglycemic Drugs Raw Material
Table 115. Key Manufacturers of Hypoglycemic Drugs Raw Materials
Table 116. Direct Channel Pros & Cons
Table 117. Indirect Channel Pros & Cons
Table 118. Hypoglycemic Drugs Typical Distributors
Table 119. Hypoglycemic Drugs Typical Customers
List of Figures
Figure 1. Hypoglycemic Drugs Picture
Figure 2. Global Hypoglycemic Drugs Revenue Market Share by Type in 2021
Figure 3. Insulin
Figure 4. DPP-4
Figure 5. GLP-1
Figure 6. SGLT-2
Figure 7. Other
Figure 8. Global Hypoglycemic Drugs Revenue Market Share by Application in 2021
Figure 9. Type 1 Diabetes
Figure 10. Type 2 Diabetes
Figure 11. Global Hypoglycemic Drugs Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 12. Global Hypoglycemic Drugs Revenue and Forecast (2017-2028) & (USD Million)
Figure 13. Global Hypoglycemic Drugs Sales (2017-2028) & (K Units)
Figure 14. Global Hypoglycemic Drugs Price (2017-2028) & (US$/Unit)
Figure 15. Global Hypoglycemic Drugs Production Capacity (2017-2028) & (K Units)
Figure 16. Global Hypoglycemic Drugs Production Capacity by Geographic Region: 2022 VS 2028
Figure 17. Hypoglycemic Drugs Market Drivers
Figure 18. Hypoglycemic Drugs Market Restraints
Figure 19. Hypoglycemic Drugs Market Trends
Figure 20. Global Hypoglycemic Drugs Sales Market Share by Manufacturer in 2021
Figure 21. Global Hypoglycemic Drugs Revenue Market Share by Manufacturer in 2021
Figure 22. Hypoglycemic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 23. Top 3 Hypoglycemic Drugs Manufacturer (Revenue) Market Share in 2021
Figure 24. Top 6 Hypoglycemic Drugs Manufacturer (Revenue) Market Share in 2021
Figure 25. Global Hypoglycemic Drugs Sales Market Share by Region (2017-2028)
Figure 26. Global Hypoglycemic Drugs Revenue Market Share by Region (2017-2028)
Figure 27. North America Hypoglycemic Drugs Revenue (2017-2028) & (USD Million)
Figure 28. Europe Hypoglycemic Drugs Revenue (2017-2028) & (USD Million)
Figure 29. Asia-Pacific Hypoglycemic Drugs Revenue (2017-2028) & (USD Million)
Figure 30. South America Hypoglycemic Drugs Revenue (2017-2028) & (USD Million)
Figure 31. Middle East & Africa Hypoglycemic Drugs Revenue (2017-2028) & (USD Million)
Figure 32. Global Hypoglycemic Drugs Sales Market Share by Type (2017-2028)
Figure 33. Global Hypoglycemic Drugs Revenue Market Share by Type (2017-2028)
Figure 34. Global Hypoglycemic Drugs Price by Type (2017-2028) & (US$/Unit)
Figure 35. Global Hypoglycemic Drugs Sales Market Share by Application (2017-2028)
Figure 36. Global Hypoglycemic Drugs Revenue Market Share by Application (2017-2028)
Figure 37. Global Hypoglycemic Drugs Price by Application (2017-2028) & (US$/Unit)
Figure 38. North America Hypoglycemic Drugs Sales Market Share by Type (2017-2028)
Figure 39. North America Hypoglycemic Drugs Sales Market Share by Application (2017-2028)
Figure 40. North America Hypoglycemic Drugs Sales Market Share by Country (2017-2028)
Figure 41. North America Hypoglycemic Drugs Revenue Market Share by Country (2017-2028)
Figure 42. United States Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Canada Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Mexico Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 45. Europe Hypoglycemic Drugs Sales Market Share by Type (2017-2028)
Figure 46. Europe Hypoglycemic Drugs Sales Market Share by Application (2017-2028)
Figure 47. Europe Hypoglycemic Drugs Sales Market Share by Country (2017-2028)
Figure 48. Europe Hypoglycemic Drugs Revenue Market Share by Country (2017-2028)
Figure 49. Germany Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. France Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. United Kingdom Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Russia Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Italy Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 54. Asia-Pacific Hypoglycemic Drugs Sales Market Share by Region (2017-2028)
Figure 55. Asia-Pacific Hypoglycemic Drugs Sales Market Share by Application (2017-2028)
Figure 56. Asia-Pacific Hypoglycemic Drugs Sales Market Share by Region (2017-2028)
Figure 57. Asia-Pacific Hypoglycemic Drugs Revenue Market Share by Region (2017-2028)
Figure 58. China Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Japan Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Korea Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. India Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Southeast Asia Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. Australia Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. South America Hypoglycemic Drugs Sales Market Share by Type (2017-2028)
Figure 65. South America Hypoglycemic Drugs Sales Market Share by Application (2017-2028)
Figure 66. South America Hypoglycemic Drugs Sales Market Share by Country (2017-2028)
Figure 67. South America Hypoglycemic Drugs Revenue Market Share by Country (2017-2028)
Figure 68. Brazil Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Argentina Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 70. Middle East & Africa Hypoglycemic Drugs Sales Market Share by Type (2017-2028)
Figure 71. Middle East & Africa Hypoglycemic Drugs Sales Market Share by Application (2017-2028)
Figure 72. Middle East & Africa Hypoglycemic Drugs Sales Market Share by Region (2017-2028)
Figure 73. Middle East & Africa Hypoglycemic Drugs Revenue Market Share by Region (2017-2028)
Figure 74. Turkey Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Egypt Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. Saudi Arabia Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. South Africa Hypoglycemic Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 78. Manufacturing Cost Structure Analysis of Hypoglycemic Drugs in 2021
Figure 79. Manufacturing Process Analysis of Hypoglycemic Drugs
Figure 80. Hypoglycemic Drugs Industrial Chain
Figure 81. Sales Channel: Direct Channel vs Indirect Channel
Figure 82. Methodology
Figure 83. Research Process and Data Source

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の低血糖薬市場2022年：インスリン、DPP-4、GLP-1、SGLT-2、その他(Global Hypoglycemic Drugs Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

世界の低血糖薬市場2022年：インスリン、DPP-4、GLP-1、SGLT-2、その他

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp